改用德诺苏马布治疗后24个月的罗莫苏马布治疗的影响:三个病例报告
Seong Hee Ahn1, Seung-Eun Lee2, Seung Hun Lee3
1Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon 22332, South Korea.
JBMR plus
|July 25, 2025
概括
之前在骨质疏松症患者中使用denosumab可能会影响romosozumab的骨密度增加. 这项研究在24个月内观察到骨矿物质密度 (BMD) 和骨周转变的变化,这些变化发生在之前用denosumab治疗的三名患者身上.
科学领域:
- 内分泌学 在内分泌学.
- 骨生物学 骨生物学 骨生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 众所周知,先前使用denosumab可以减少骨矿物质密度 (BMD) 的增加,随后使用romosozumab治疗.
- 在患者之前暴露于denosumab后,在经过24个月的罗莫苏祖马布治疗后,关于BMD变化的数据有限.
研究的目的:
- 在骨质疏松症患者在24个月的罗莫苏祖马布治疗后评估BMD变化和骨周转率标志物.
主要方法:
- 三名骨质疏松症患者先前使用了denosumab,接受了24个月的罗莫苏祖马布治疗.
- 测量了腰椎 (LS),大腿 (FN) 和全部 (TH) 的骨矿物质密度 (BMD).
- 评估了骨循环标记物,包括1型原蛋白N端 (P1NP) 和I型原蛋白C端端 (CTX).
主要成果:
- 观察到不同的BMD反应:在所有情况下,LS-BMD在24个月内显著增加 (7.4%7.9%).
- FN-BMD和TH-BMD的变化不一致,一些病例显示微小或负面的变化.
- 骨循环标记物 (P1NP和CTX) 呈现出不同的模式,一些患者最初呈现增加,随后下降,一名患者呈现持续增加.
结论:
- 在先前使用过登索苏马布的患者中,经过24个月的罗莫苏马布治疗方案,产生异质的BMD结果和骨循环标记反应.
- 这些发现凸显了先前的抗吸收疗法和合成骨药之间的复杂相互作用.
- 需要进行更大的受控研究来验证这些观察结果并指导临床实践.
相关概念视频
01:31Osteoclasts in Bone Remodeling
3.2K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.2K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
225
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
225
01:40Bone Remodeling
38.5K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.5K
01:26Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
01:16Insulin: Dosing Regimen and Adverse Effects
262
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
262